Imfinzi

CAMBRIDGE, UK, April 2, 2026 AstraZeneca has announced positive results from the Phase III EMERALD-3 trial, where a combination...

CAMBRIDGE, UK, March 16, 2026 AstraZeneca has received European Commission approval for Imfinzi (durvalumab) as the first and only...

Madrid, Spain – October 11, 2025 – AstraZeneca presented groundbreaking clinical trial results from four major Phase III studies...